SUMMARY A self-tuning, closed-loop computerized system was used to maintain atracurium-induced neuromuscular blockade in patients undergoing routine lower abdominal gynaecological surgery. The controller is based on a unique algorithm which utilizes a bi-exponential model wherein two of the variables are estimated on-line. This enables the system to optimize the sizes of subsequent bolus doses according to patient sensitivity. In this study an initial bolus of 0.3 mg kg'' was given in a trade-off aimed at achieving earlier intubating conditions rather than taking control of relaxation ab initio

PATIENTS, MATERIALS AND METHODS
The Control System
The working system ( fig. 1 ) consists of the nerve stimulator, force transducer, microprocessor controller, syringe pump and a chart recorder. Inputs to the controller are from the force transducer and keyboard, and outputs are to an alphanumeric display, cassette tapedrive for data logging and off-line analysis, the recorder, and the syringe pump driver. A general overview of the elements is given below; the reader will be referred to previous work for the considerable theoretical background and practical detail. 
The algorithm
The algorithm is aimed at achieving and maintaining a selectable setpoint of twitch depression. It is based on a dose-response model described previously [1, 3, 4] , and which can be summarized as follows:
The model is bi-compartmental, the peripheral compartment being the site of action of the drug. It is important to note that this model does not necessarily have any relation to traditional pharmacokinetic models based on plasma concentrations [5] . It is described by a single bolus response of the concentration in the " effect" compartment given by: were x(t) is the time dependent concentration of the drug in the effect compartment, a and ft are the time constants of the model, 0 is a dead time, A is the " sensitivity " of the response, and U is the size of the bolus dose.
Since dose schedules rather different from a single bolus are used, the above equation is converted by straightforward algebraic manipulation to an input-output relationship in the discrete-or sample-time domain given by:
where k is the sample number, z' 1 is the discrete time backward shift operator, G is the gain given by P(e~*'-e"" r ) where T is the sampling period, U(k) is the bolus input at the kth sampling instant, Downloaded from https://academic.oup.com/bja/article-abstract/61/6/685/248025 by guest on 27 July 2018 and P l and P 2 are the poles of the model given by P x = e" 1 " and P 2 = e^r. The pharmacodynamic relationship between the effect and the concentration in the effect compartment is obtained by using the "logistic" relationship:
where T(k) is the twitch response at the sampling instant and B T is the variable which regulates the sigmoidal shape of the pharmacodynamic relationship.
The variables G and B T are estimated on-line by an expanding memory, steepest-descent, nonlinear least-squares algorithm and, following previous findings that these estimates converged within 200 sampling periods, their continuous reestimation is terminated and they remain fixed after this period.
P Y and P 2 were not estimated on-line as simulation studies [1] indicated that little improvement could be achieved over choosing population constants obtained in this particular application from previous work on controlled atracuriuminduced neuromuscular blockade [2] .
The model and the parameters obtained are used in a novel control algorithm developed for this application [1] . The controller reads the twitch response every 10 s and administers a bolus dose every 1 min during the operation from initiation to the end of the control (of course, at many 1 -min instants-which we refer to below as "control instants"-the dose administered is zero). At each control instant, the controller predicts future degrees of paralysis from the doses already administered and locates the maximum by using the model described above and a linear state estimator. It then calculates by a numerical method the present dose that must be administered in order to take the maximum to the desired endpoint. It has been found that this algorithm (which caters for positive-input systems and into which category this system falls as it cannot remove drug from the body) is insensitive to the patient dead time [4] and provides excellent control performance for both the induction and the maintenance of paralysis [1] .
The microprocessor [6] The CPU board utilizes the full co-processing features of an Intel 8088 CPU and 8087 floatingpoint numerics processor and can, consequently, cope more than adequately with the computational load imposed by the control algorithm. There are additional cards for (i) memory, (ii) keyboard controller, (iii) serial input/output, and (iv) digital cassette tape interface equipped with an 8085 microprocessor. The fifth card was designed specifically for the unit and provides an interface for the twitch measurement and syringe driver systems.
The software [6] The control program was written in Intel 8086/ 88 assembly language and runs as a single task on the native computer system without the use of any operating system. Its function is to implement the control algorithm, and requires certain keyboardentered information on initiation (see Parameter Entry below). The software runs as a continuous loop, calling two major subroutines, one of which collects the twitch data, while the other performs the control calculation and issues commands to the syringe driver. All twitch-response and calculated control data may be logged on tape cassette for subsequent at-leisure evaluation on a Univac 11/08 mainframe computer-an option which is only necessary as a research and development tool during the refinement of the program or parameter estimation of new drugs.
Twitch data validity checks are performed by ensuring that there has been no over-or underflow in the analogue-to-digital converter of the measurement system, that pulses in the train-of-four (TOF) are monotonically decreasing, and that pulse arrival is at an interval between 400 and 700 ms.
The measurement system [6] Neuromuscular transmission is measured by stimulating the ulnar nerve via two Medicotest paediatric silver-silver chloride surface electrodes placed over the nerve on the volar aspect of the wrist. The stimulus consists of a supramaximal TOF pattern of pulses each always less than 200 us in duration at 0.5-s intervals every 10 s. The outstretched hand is strapped to a specially constructed armboard on which is fixed the Perspex housing of the force displacement transducer unit, and the thumb is secured to and activates a plunger mounted in a linear precision bearing so that the load is transmitted via a cantilever to two strain gauges forming half of a Wheatstone Bridge. The system has a working range of 0-100 N and the thumb is preloaded with 100-150 g.
The syringe driver [6] The unit consists of an opto-isolated batterydriven motor which drives the plunger of a standard 20-ml disposable syringe via a worm gear and flywheel arrangement. The flywheel has circumferential holes spaced 30° apart which allow pulses to be sent to the computer with rotation through a light beam aimed at a photocell. All atracurium boluses were administered as a 0.1% solution in 0.9 % normal saline into a freely running i.v. infusion. The pump is capable of delivering fluid at a rate of 1 ml s" 1 and 20 mg thus takes only 20 s to be injected, which is an order of magnitude smaller than the time constant of the drug. Individual boluses and accumulated dose are displayed by the computer, and control may be overridden by switching the driver off-line.
Parameter entry
Apart from standard entries such as the case identification header, date and patient weight, the operator needs to supply die controller with other menu-selectable items of information.
(1) The variables P : and P 2 for atracurium and the gains of the linear state estimator which, as mentioned, were entered as default values derived in a previous study. Under working clinical conditions these items would be automatically entered when "Atracurium" was selected from a drug menu.
(2) The size of die initial bolus-in diis instance 0.3 mg kg'
1 . (3) The ratio which is to be controlled. The menu includes STR, being the ratio of the heights of the first twitch of die TOF before and after administration of the blocking agent, and T2 and T4 ratios, being the ratio of the height of die relevant numbered twitch to the first at any stage of blockade. In diis instance STR was used and thus necessitated measuring die first twitch height under stable anaesthetized conditions before die administration of the neuromuscular blocker. (4) The setpoint for block-in diis instance 15 %. This may be altered by keyboard entry during the run.
Operation
The procedure is conveniently considered as occurring in four stages, namely the monitoring, relaxation, regulation and recovery phases.
Monitoring phase. When a stable level of anaesthesia has been achieved, die system monitors die TOF until the magnitude of all four responses has been stable for at least 30 s, thus providing baseline values.
Relaxation phase. The initial bolus of atracurium 0.3 mg kg" 1 is injected and the system then monitors the patient's response, modifying accordingly diose internal parameters which determine die calculation of subsequent doses. If setpoint is not achieved, further boluses of drug are given under microprocessor control. This phase is further subdivided into two subphases: the time from injecting the bolus to first reaching setpoint, and the overshoot period from the time of first reaching setpoint to the time of returning to setpoint. Regulation phase. This begins when blockade returns from overshoot to setpoint and ends when control is relinquished at the end of surgery. During this phase the system controls blockade by administering the dose calculated to maintain setpoint. Self-tuning continues for the 200-sample period, which takes approximately 35 min after initiation of control. Up till then the algorithm thus allows for modification of the size of subsequent doses according to both patient response to the previous dose(s) and deviation from setpoint, and thereafter only according to deviation from setpoint.
Recovery phase. Following manual discontinuation of control, the residual blockade is antagonized, and monitoring is continued until the T4 ratio reaches 70%.
Patients
The design of the study was approved by the hospital Ethics Committee and informed consent was obtained from all subjects. Eleven ASA Class I or II patients scheduled to undergo elective lower abdominal gynaecological surgery were selected from routine lists, the only other exclusions being any form of muscular, neuromuscular or neurological pathology, or the concomitant use of drugs known to affect neuromuscular transmission.
Anaesthetic technique
Patients were premedicated with diazepam 10 mg given by mouth 2 h before the start of surgery. Anaesthesia was induced with fentanyl 100 |ig and thiopentone 3-5 mg kg" 1 , the vocal chords and upper trachea topically anaesthetized with 4% lignocaine spray 120-160 mg, and anaesthesia subsequently maintained with 70 % nitrous oxide and 0.5 % halothane in oxygen. Fentanyl was given in 50-ug boluses as determined by patient response to painful stimuli during the procedure. When a stable level of anaesthesia had been achieved as determined by the control system, it then injected the initial atracurium bolus and assumed further control of neuromuscular blockade. Intubation was performed when the STR had decreased to 15%, and the lungs were ventilated to maintain normocarbia (as monitored by capnography (Datex Normocap)). Other monitoring included sphygmomanometric measurement of arterial pressure and a continuous electrocardiographic display. Residual neuromuscular block was antagonized with neostigmine 2.5 mg and glycopyrrolate 0.4 mg.
RESULTS
The mean weight of the patients was 66.82 (SD 4.9) kg and their mean age 37 (9) yr. Intubating and operating conditions as afforded by the technique were always good. Atracurium itself produced minimal but no clinically significant haemodynamic changes and, despite the fact that two of the patients had a history of mild asthma, there was no clinical evidence of increased airway resistance.
The pharmacodynamic results are set out in table I. All patients achieved setpoint with the initial bolus, the average time being 2.47 (0.95) min with a maximum of 4.67 and a minimum of 1.5 min. The overshoot duration was 22.77 (11.26) min, ranging from 3 to 41 min. The regulation phase duration averaged 51.39 (35.67) min, the longest being 136.17 min. Patient 8, who was particularly sensitive to the drug, did not recover from her overshoot for 37 min after setpoint was reached and as this coincided with the end of surgery, no regulation control was necessary.
The average dose of drug used during the regulation phase was 0.34 (0.07) mg kg" 1 h"
1 . This figure obviously does not include the initial bolus.
The offset during regulation is used as a measure of the pharmacodynamic control afforded by the system and is expressed as the deviation of the STR from the setpoint during the regulation phase. The values tabled are all negative, which is not surprising in view of the fact that the system is triggered before setpoint is re-achieved. The value of-4.74 (3.36)% for all patients as a group thus represents a mean STR of 10.26% once setpoint had been reached. The average standard deviation of the individual offsets was 4.31 (2.53)%, indicating a very tight degree of control around setpoint. A plot demonstrating the control of blockade in patient 10 is shown in figure 2 .
The induction-blocker time in table I refers to the time between induction of anaesthesia and the injection of the initial bolus, and incorporates the time needed to seat the patient's arm on the board, preload the transducer system and for the initial monitoring by the system to be completed. This period was surprisingly short, with a median of 7 min.
DISCUSSION
Control of neuromuscular blockade during clinical anaesthesia is beset by two major problems. The first is that of patient variability in response to the neuromuscular blocking drug. The exact reasons as to this differing susceptibility are incompletely understood and there is no reliable means of estimating sensitivity to the agent used before the administration of the drug. The second problem lies in the heavy-handed, traditional method of administration of neuromuscular blocking drugs. Because the anaesthetist requires rapid onset of profound blockade for intubation, the drugs are usually administered by means of a large initial bolus which produces a far greater degree of block than is required by either anaesthetist or surgeon. When the effect of this wears off and blockade becomes inadequate, further smaller boluses are given. The outcome is an unstable pharmacodynamic profile fluctuating between overdosage and underdosage. Ideal kinetic steady-state management would involve a bolus dose to achieve the necessary plasma concentration of drug rapidly, an exponentially declining infusion to accommodate for redistribution to peripheral compartments, and a second infusion to compensate for drug elimination. Apart from the logistical problems of implementing such a technique, myoneural blockers are not amenable to pharmacodynamic control based on central compartment plasma concentrations-the concentration-response relationship is variable and inconsistent. It would thus seem more appropriate to titrate drug against effect in the time-honoured i.v. induction tradition.
Our initial investigations, using a non-linear least-squares data fitting routine and aimed at determining a suitable model for use in automated control of neuromuscular blockade with tubocurarine, indicated that a bi-exponential function sufficed [4] . In the search for a suitable controller, both a discrete time proportional-integral-derivative controller and the self-tuning controller of Clarke and Gawthorp [7] were simulated and found to give unsatisfactory results, leading us to design a self-tuning controller the algorithm of which utilized our pharmacodynamic model [1] . On-line parameter estimation and the use of the Rametti-Bradlow controller successfully overcame die problems of the dead time in patient response attributable to circulation, the nonlinearity of the pharmacodynamic response resulting from initial silent receptor occupancy, the long-acting effect of non-depolarizing neuromuscular blocking agents, and the wide individual variation. Tubocurarine was chosen as a starting point because of the relative wealth of documented dynamic data available on this agent and because its long time constants provide a more stringent test.
Closed-loop systems have recently been described for the administration of pancuronium using a proportional controller [8] , of vecuronium using an on-off infusion controller [9] , and of atracurium by Webster and Cohen using a proportional controller [10] . Bearing in mind that our initial bolus dose was less than that used by the latter workers (0.3 v. 0.5 mg kg"') and that our control was only very slightly higher than dieirs (10.26 v. 8.9%), our maintenance infusion rate was considerably lower (0.34 v. 0.45 mg kg" 1 h" 1 ). As there is an obvious dose relationship with the time to intubation and it is generally desirable to be able to intubate as soon as possible, our trade-off in using 0.3 mg kg" 1 as an intubating dose resulted in the clinically acceptable average time to setpoint of 2.47 min, intubation conditions being satisfactory in all patients.
In some instances there appeared to be a proportional relationship between a rapid onset of paralysis and a long duration of overshoot (patients 4, 8 and 9), but regression analysis of time to setpoint against duration of overshoot did not confirm an overall correlation. Regression analysis of time to setpoint against drug administration rate during the regulation phase also failed to expose significant correlation. Thus a rapid onset of paralysis does not necessarily mean that less drug will be required for the maintenance of blockade. This, together with the large ranges in all the pharmacodynamic parameters, underscores once again the need for individualization of dosage. There did, however, appear to be an inverse relationship between the duration of overshoot and the drug administration rate during the regulation phase.
Disadvantages of the system are largely related to the measurement system. Setting up the mechanical transducer with immobilization of the arm and preloading is time-consuming and fussy. Electromyographic techniques more resistant to movement noise would be an obvious improvement, although diathermy interference would then become a nuisance. Full screen trended online data display would also be an advantage.
We believe that further development aimed at a consumer market would bring inexpensive closed-loop administration of neuromuscular blocking drugs within the realm of everyday practical anaesthesia. The special advantage of attaining a stable predetermined level of neuromuscular blockade at the most economical drug consumption rate is that reversible blockade is rapidly attained, minimizing the hazard of recurarization and contributing significantly to patient safety.
